German quantum healthcare company NVision has raised $55 million in a Series B round announced on May 13, 2026, as it broadens its focus from quantum sensing to quantum computing.
The financing was anchored by Abbott and included a $17 million venture loan from the European Investment Bank. Existing and returning backers including Playground Global, Matterwave/b2ventures, and Entrée Capital also participated. The new round brings NVision’s total funding to $120 million.
Based in Ulm, NVision is known for POLARIS, a quantum-enhanced sensing platform designed to boost MRI signals from sugar-based imaging agents and enable real-time measurement of metabolism on standard MRI systems. The company said the fresh capital will support its move into quantum computing through its Photonic Integrated Quantum Circuits, or PIQC, platform.
NVision says the expansion is aimed at building an end-to-end quantum-based approach to designing and validating therapies, combining drug design capabilities with faster biological validation in healthcare applications.
The financing was anchored by Abbott and included a $17 million venture loan from the European Investment Bank. Existing and returning backers including Playground Global, Matterwave/b2ventures, and Entrée Capital also participated. The new round brings NVision’s total funding to $120 million.
Based in Ulm, NVision is known for POLARIS, a quantum-enhanced sensing platform designed to boost MRI signals from sugar-based imaging agents and enable real-time measurement of metabolism on standard MRI systems. The company said the fresh capital will support its move into quantum computing through its Photonic Integrated Quantum Circuits, or PIQC, platform.
NVision says the expansion is aimed at building an end-to-end quantum-based approach to designing and validating therapies, combining drug design capabilities with faster biological validation in healthcare applications.